NanoPhoria: Delivering inhalable biologics to the heart

Using a two-level inhalable particle design, NanoPhoria is exploiting the unique connection between the lungs and heart to deliver peptides and nucleic acids to cardiomyocytes, whose inaccessibility has historically limited the use of biologics in cardiovascular diseases.

NanoPhoria s.r.l. (NanoPhoria Bioscience) has designed its “Nano-in-Micro” platform to deliver concentrated doses of therapy straight from the lung to the heart, before systemic dilution in the larger circulation. The company’s € 83.5 million series A funding, the largest on record for an Italian company, is expected to take NanoPhoria through Phase IIa in the clinic for its lead indication, heart failure with reduced ejection fraction (HFrEF)...